{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T23:40:02Z","timestamp":1750722002495,"version":"3.41.0"},"reference-count":69,"publisher":"Georg Thieme Verlag KG","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Fortschr Neurol Psychiatr"],"abstract":"Zusammenfassung<\/jats:title>Trazodon ist ein dualserotonerges Antidepressivum mit vernachl\u00e4ssigbaren\n anticholinergischen Effekten, das in niedrigen Dosierungen sedierend, hypnotisch\n und anxiolytisch und in h\u00f6heren Dosierungen antidepressiv wirkt. Die\n Vertr\u00e4glichkeit ist gut und die wichtigsten unerw\u00fcnschten Arzneimittelwirkungen\n sind orthostatische Hypotonie und Benommenheit\/Sedierung mit erh\u00f6htem\n Sturzrisiko, dosisabh\u00e4ngige moderate Erh\u00f6hung der QTc-Zeit mit dem Risiko f\u00fcr\n ventrikul\u00e4re Herzrhythmusst\u00f6rungen und Priapismus. Trazodon weist\n evidenzbasierte antidepressive Wirksamkeit bei \u00e4lteren kognitiv unauff\u00e4lligen\n Menschen auf und es gibt Hinweise, dass Trazodon auch bei Menschen mit\n Depression und komorbider Demenz\/kognitiver Dysfunktion antidepressiv wirksam\n ist. Bei Menschen mit Demenz und Schlafst\u00f6rungen verbessert Trazodon die\n Schlafeffizienz und verl\u00e4ngert die n\u00e4chtliche Schlafdauer. Zwar existieren\n Hinweise auf eine Wirksamkeit von Trazodon zur Behandlung von psychischen und\n Verhaltenssymptomen bei Demenz (v.\u2009a. Agitation) und wird Trazodon ausdr\u00fccklich\n zur Behandlung von motorischer Unruhe bei frontotemporaler Demenz empfohlen. Die\n Evidenz daf\u00fcr ist aber eher schwach. Auf der Basis von Tierversuchen ergeben\n sich Hinweise auf neuroprotektive Effekte von Trazodon durch Hemmung der f\u00fcr\n einige neurodegenerative Erkrankungen typischen \u00dcberaktivierung der \u201eunfolded\n protein response\u201c (UPR). Zudem konnte gezeigt werden, dass die regelm\u00e4\u00dfige\n Anwendung von Trazodon die Verschlechterung der kognitiven Funktion bei\n Patienten mit der Diagnose einer Demenz vom Alzheimer-Typ verz\u00f6gert. Gegenw\u00e4rtig\n ist jedoch noch unklar, ob Trazodon signifikante neuroprotektive Effekte beim\n Menschen aufweist.<\/jats:p>","DOI":"10.1055\/a-2600-3773","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T23:01:28Z","timestamp":1750719688000},"source":"Crossref","is-referenced-by-count":0,"title":["Trazodon in der gerontopsychiatrischen Versorgung"],"prefix":"10.1055","author":[{"given":"Maximilian","family":"Gahr","sequence":"additional","affiliation":[{"name":"Krankenhaus f\u00fcr Psychiatrie, Psychotherapie und Psychosomatische\n Medizin Schlo\u00df Werneck, Werneck, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berthold","family":"Merz","sequence":"additional","affiliation":[{"name":"Krankenhaus f\u00fcr Psychiatrie, Psychotherapie und Psychosomatische\n Medizin Schlo\u00df Werneck, Werneck, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2025,6,23]]},"reference":[{"key":"ref1","first-page":"CD006211","article-title":"Comprehensive geriatric assessment for older adults admitted to hospital","volume":"9","author":"G Ellis","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3389\/fneur.2012.00073","article-title":"Behavioral and psychological symptoms of dementia","volume":"3","author":"J Cerejeira","year":"2012","journal-title":"Front Neurol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1111\/j.1468-1331.2012.03784.x","article-title":"EFNS-ENS Guidelines on the diagnosis and management of disorders associated with\n dementia","volume":"19","author":"S Sorbi","year":"2012","journal-title":"Eur J Neurol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/JCP.0b013e3182a6096e","article-title":"Use and safety of antipsychotics in behavioral disorders in elderly people with\n dementia","volume":"34","author":"P Gareri","year":"2014","journal-title":"J Clin Psychopharmacol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"afad091","DOI":"10.1093\/ageing\/afad091","article-title":"Pharmacological treatment of neuropsychiatric symptoms of dementia: a network\n meta-analysis","volume":"52","author":"Y Y Huang","year":"2023","journal-title":"Age Ageing"},{"key":"ref7","first-page":"CD013304","article-title":"Antipsychotics for agitation and psychosis in people with Alzheimer\u2019s disease\n and vascular dementia","volume":"12","author":"V Muhlbauer","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1192\/bjo.2024.798","article-title":"Prevalence of central nervous system-active polypharmacy in a cohort of older\n adults in Argentina","volume":"10","author":"A Ferraris","year":"2024","journal-title":"BJPsych Open"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1001\/jama.2021.1195","article-title":"Prevalence of Central Nervous System-Active Polypharmacy Among Older Adults With\n Dementia in the US","volume":"325","author":"D T Maust","year":"2021","journal-title":"JAMA"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"e70014","DOI":"10.1002\/gps.70014","article-title":"Association of Psychotropic Prescriptions With Non-Registered Indications and\n the Risk of Mortality in Older Adults: A Danish Nationwide Cohort Study","volume":"39","author":"K Ishtiak-Ahmed","year":"2024","journal-title":"Int J Geriatr Psychiatry"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.cger.2019.11.010","article-title":"Managing Behavioral and Psychological Symptoms of Dementia","volume":"36","author":"L B Gerlach","year":"2020","journal-title":"Clin Geriatr Med"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1111\/jgs.14897","article-title":"Off-Label Prescribing of Second-Generation Antipsychotics to Elderly Veterans\n with Posttraumatic Stress Disorder and Dementia","volume":"65","author":"T P Semla","year":"2017","journal-title":"J Am Geriatr Soc"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"775","DOI":"10.7326\/0003-4819-146-11-200706050-00006","article-title":"Antipsychotic drug use and mortality in older adults with dementia","volume":"146","author":"S S Gill","year":"2007","journal-title":"Ann Intern Med"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1001\/archinte.168.10.1090","article-title":"Antipsychotic therapy and short-term serious events in older adults with\n dementia","volume":"168","author":"P A Rochon","year":"2008","journal-title":"Arch Intern Med"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s40263-012-0010-5","article-title":"Rediscovering trazodone for the treatment of major depressive disorder","volume":"26","author":"A Fagiolini","year":"2012","journal-title":"CNS Drugs"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1370\/afm.1687","article-title":"Efficacy and acceptability of pharmacological treatments for depressive\n disorders in primary care: systematic review and network meta-analysis","volume":"13","author":"K Linde","year":"2015","journal-title":"Ann Fam Med"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"e2118441","DOI":"10.1001\/jamanetworkopen.2021.18441","article-title":"Comparison of Medication Prescribing Before and After the COVID-19 Pandemic\n Among Nursing Home Residents in Ontario, Canada","volume":"4","author":"M A Campitelli","year":"2021","journal-title":"JAMA Netw Open"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s40266-016-0380-3","article-title":"Changing Pattern of Sedative Use in Older Adults: A Population-Based Cohort\n Study","volume":"33","author":"A Iaboni","year":"2016","journal-title":"Drugs Aging"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1517\/14656566.2012.699523","article-title":"Off-label uses of trazodone: a review","volume":"13","author":"L Bossini","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"ref20","first-page":"331","article-title":"Trazodone. A review of its pharmacology, therapeutic use in depression and\n therapeutic potential in other disorders","volume":"4","author":"M Haria","year":"1994","journal-title":"Drugs Aging"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1007\/BF00172631","article-title":"Overview of USA controlled trials of trazodone in clinical depression","volume":"95","author":"J P Feighner","year":"1988","journal-title":"Psychopharmacology (Berl)"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"734","DOI":"10.7326\/0003-4819-149-10-200811180-00008","article-title":"Comparative benefits and harms of second-generation antidepressants: background\n paper for the American College of Physicians","volume":"149","author":"G Gartlehner","year":"2008","journal-title":"Ann Intern Med"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"449","DOI":"10.12740\/PP\/182933","article-title":"Clinical experience with parenteral trazodone in mood disorders: A literature\n review","volume":"58","author":"C Crapanzano","year":"2024","journal-title":"Psychiatr Pol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1017\/S1092852900024020","article-title":"Mechanism of action of trazodone: a multifunctional drug","volume":"14","author":"S M Stahl","year":"2009","journal-title":"CNS Spectr"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s40263-013-0071-0","article-title":"Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders:\n rationale and current status of research","volume":"27","author":"P Celada","year":"2013","journal-title":"CNS Drugs"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0014-2999(00)00378-2","article-title":"Effects of trazodone on neurotransmitter release from rat mossy fibre cerebellar\n synaptosomes","volume":"400","author":"B Garrone","year":"2000","journal-title":"Eur J Pharmacol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/sj.npp.1300057","article-title":"Synergistic action of 5-HT2A antagonists and selective serotonin reuptake\n inhibitors in neuropsychiatric disorders","volume":"28","author":"G J Marek","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0014-2999(99)00644-5","article-title":"Trazodone increases extracellular serotonin levels in the frontal cortex of\n rats","volume":"383","author":"M Pazzagli","year":"1999","journal-title":"Eur J Pharmacol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2165\/00003495-198121060-00001","article-title":"Trazodone: a review of its pharmacological properties and therapeutic use in\n depression and anxiety","volume":"21","author":"R N Brogden","year":"1981","journal-title":"Drugs"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1111\/cts.13253","article-title":"Estimation of brain receptor occupancy for trazodone immediate release and once\n a day formulations","volume":"15","author":"L Oggianu","year":"2022","journal-title":"Clin Transl Sci"},{"key":"ref32","first-page":"2084","article-title":"Pharmacokinetics and metabolism of trazodone in man (author\u2019s transl)","volume":"26","author":"R Jauch","year":"1976","journal-title":"Arzneimittelforschung"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1055\/s-0037-1600991","article-title":"Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology:\n Update 2017","volume":"51","author":"C Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1365-2125.1981.tb01157.x","article-title":"Trazodone \u2013 a new assay procedure and some pharmacokinetic parameters","volume":"11","author":"S I Ankier","year":"1981","journal-title":"Br J Clin Pharmacol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3389\/fphar.2015.00224","article-title":"Pharmacokinetics of single oral dose trazodone: a randomized, two-period,\n cross-over trial in healthy, adult, human volunteers under fed condition","volume":"6","author":"P Kale","year":"2015","journal-title":"Front Pharmacol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1365-2125.1983.tb02180.x","article-title":"Pharmacokinetic and pharmacodynamic characteristics of trazodone in the\n elderly","volume":"16","author":"A J Bayer","year":"1983","journal-title":"Br J Clin Pharmacol"},{"key":"ref37","first-page":"369","article-title":"Investigations on the absorption and distribution of trazodone or AF 1161 in\n rats, dogs and humans","volume":"109","author":"B Catanese","year":"1970","journal-title":"Boll Chim Farm"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1023\/A:1006953923305","article-title":"Metabolism of some \u201csecond\u201d- and \u201cfourth\u201d-generation antidepressants: iprindole,\n viloxazine, bupropion, mianserin, maprotiline, trazodone, nefazodone, and\n venlafaxine","volume":"19","author":"S Rotzinger","year":"1999","journal-title":"Cell Mol Neurobiol"},{"key":"ref39","first-page":"572","article-title":"Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human\n sources","volume":"26","author":"S Rotzinger","year":"1998","journal-title":"Drug Metab Dispos"},{"key":"ref40","first-page":"216","article-title":"Active drug metabolites. An overview of their relevance in clinical\n pharmacokinetics","volume":"10","author":"S Garattini","year":"1985","journal-title":"Clin Pharmacokinet"},{"key":"ref41","first-page":"272","article-title":"The newer antidepressant drugs and their cardiovascular effects","volume":"20","author":"A H Glassman","year":"1984","journal-title":"Psychopharmacol Bull"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1186\/s12877-022-03165-6","article-title":"Falls, healthcare resources and costs in older adults with insomnia treated with\n zolpidem, trazodone, or benzodiazepines","volume":"22","author":"D T Amari","year":"2022","journal-title":"BMC Geriatr"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"E1376","DOI":"10.1503\/cmaj.180551","article-title":"Comparative risk of harm associated with trazodone or atypical antipsychotic use\n in older adults with dementia: a retrospective cohort study","volume":"190","author":"J A Watt","year":"2018","journal-title":"CMAJ"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJM199809243391303","article-title":"Antidepressants and the risk of falls among nursing home residents","volume":"339","author":"P B Thapa","year":"1998","journal-title":"N Engl J Med"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejphar.2005.01.009","article-title":"Effect of trazodone on hERG channel current and QT-interval","volume":"510","author":"P Tarantino","year":"2005","journal-title":"Eur J Pharmacol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"469","DOI":"10.4088\/JCP.v66n0409","article-title":"A review of the evidence for the efficacy and safety of trazodone in\n insomnia","volume":"66","author":"W B Mendelson","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1002\/jcph.1640","article-title":"Effect of 3 Single Doses of Trazodone on QTc Interval in Healthy Subjects","volume":"60","author":"V Tellone","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1192\/j.eurpsy.2024.11","article-title":"The risk of antidepressant-induced hyponatremia: A meta-analysis of\n antidepressant classes and compounds","volume":"67","author":"T Gheysens","year":"2024","journal-title":"Eur Psychiatry"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.2147\/NDT.S434130","article-title":"Trazodone in the Management of Major Depression Among Elderly Patients with\n Dementia: A Narrative Review and Clinical Insights","volume":"19","author":"A Fagiolini","year":"2023","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1097\/00002826-198901001-00005","article-title":"Clinical activity and tolerability of trazodone, mianserin, and amitriptyline in\n elderly subjects with major depression: a controlled multicenter trial","volume":"12","author":"A C Altamura","year":"1989","journal-title":"Clin Neuropharmacol"},{"key":"ref51","first-page":"294","article-title":"Fluoxetine versus trazodone: efficacy and activating-sedating effects","volume":"52","author":"C M Beasley","year":"1991","journal-title":"J Clin Psychiatry"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1177\/089198878900200407","article-title":"Fluoxetine versus trazodone in depressed geriatric patients","volume":"2","author":"W E Falk","year":"1989","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1097\/00002826-198901001-00009","article-title":"A comparative study of conventional and controlled-release formulations of\n trazodone in elderly depressed patients","volume":"12","author":"A J Bayer","year":"1989","journal-title":"Clin Neuropharmacol"},{"key":"ref54","first-page":"63","article-title":"Oral 5\u2019-methyltetrahydrofolic acid in senile organic mental disorders with\n depression: results of a double-blind multicenter study","volume":"5","author":"M Passeri","year":"1993","journal-title":"Aging (Milano)"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s40263-024-01110-2","article-title":"Effects of Trazodone on Sleep: A Systematic Review and Meta-analysis","volume":"38","author":"M Kokkali","year":"2024","journal-title":"CNS Drugs"},{"key":"ref56","first-page":"CD009178","article-title":"Pharmacotherapies for sleep disturbances in dementia","volume":"11","author":"J McCleery","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/00019442-199705010-00008","article-title":"A double-blind comparison of trazodone and haloperidol for treatment of\n agitation in patients with dementia","volume":"5","author":"D L Sultzer","year":"1997","journal-title":"Am J Geriatr Psychiatry"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1046\/j.1532-5415.2001.49256.x","article-title":"Does behavioral improvement with haloperidol or trazodone treatment depend on\n psychosis or mood symptoms in patients with dementia?","volume":"49","author":"D L Sultzer","year":"2001","journal-title":"J Am Geriatr Soc"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1212\/WNL.55.9.1271","article-title":"Treatment of agitation in AD: a randomized, placebo-controlled clinical\n trial","volume":"55","author":"L Teri","year":"2000","journal-title":"Neurology"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1159\/000077171","article-title":"Frontotemporal dementia: a randomised, controlled trial with trazodone","volume":"17","author":"F Lebert","year":"2004","journal-title":"Dement Geriatr Cogn Disord"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"e16446","DOI":"10.1111\/ene.16446","article-title":"Pharmacotherapy for behavioural manifestations in frontotemporal dementia: An\n expert consensus from the European Reference Network for Rare Neurological\n Diseases (ERN-RND)","volume":"31","author":"C Wittebrood","year":"2024","journal-title":"Eur J Neurol"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"1103039","DOI":"10.3389\/fnagi.2023.1103039","article-title":"Comparative efficacy and safety of antidepressant therapy for the agitation of\n dementia: A systematic review and network meta-analysis","volume":"15","author":"K Chen","year":"2023","journal-title":"Front Aging Neurosci"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1365-2125.1983.tb04977.x","article-title":"Trazodone enhances sleep in subjective quality but not in objective\n duration","volume":"16","author":"I Montgomery","year":"1983","journal-title":"Br J Clin Pharmacol"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1272\/jnms.69.333","article-title":"Effects of trazodone and imipramine on the biological rhythm: an analysis of\n sleep EEG and body core temperature","volume":"69","author":"H Suzuki","year":"2002","journal-title":"J Nippon Med Sch"},{"key":"ref66","first-page":"13","article-title":"Sleep laboratory evaluation of the effects and efficacy of trazodone in\n depressed insomniac patients","volume":"51","author":"M B Scharf","year":"1990","journal-title":"J Clin Psychiatry"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1007\/BF00172629","article-title":"Effects of trazodone on the sleep of depressed subjects \u2013 a polygraphic\n study","volume":"95","author":"J Mouret","year":"1988","journal-title":"Psychopharmacology (Berl)"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"911","DOI":"10.3233\/JAD-181145","article-title":"Long-Term Trazodone Use and Cognition: A Potential Therapeutic Role for\n Slow-Wave Sleep Enhancers","volume":"67","author":"A L La","year":"2019","journal-title":"J Alzheimers Dis"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1007\/s00228-021-03161-6","article-title":"The effects of trazodone on human cognition: a systematic review","volume":"77","author":"AM G Goncalo","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nature11058","article-title":"Sustained translational repression by eIF2alpha-P mediates prion\n neurodegeneration","volume":"485","author":"J A Moreno","year":"2012","journal-title":"Nature"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1093\/brain\/awx074","article-title":"Repurposed drugs targeting eIF2α-P-mediated translational repression\n prevent neurodegeneration in mice","volume":"140","author":"M Halliday","year":"2017","journal-title":"Brain"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"S205","DOI":"10.3233\/JAD-230635","article-title":"A Randomized-Controlled Trial Targeting Cognition in Early Alzheimer\u2019s Disease\n by Improving Sleep with Trazodone (REST)","volume":"101","author":"E Eyob","year":"2024","journal-title":"J Alzheimers Dis"}],"container-title":["Fortschritte der Neurologie \u00b7 Psychiatrie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2600-3773.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T23:01:38Z","timestamp":1750719698000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2600-3773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,23]]},"references-count":69,"URL":"https:\/\/doi.org\/10.1055\/a-2600-3773","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0720-4299","1439-3522"],"issn-type":[{"value":"0720-4299","type":"print"},{"value":"1439-3522","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,23]]}}}